The Pediatric Neurology Device market is going through powerful changes driven by mechanical advancements, increasing awareness of pediatric neurological disorders, and a developing emphasis on early diagnosis and mediation. This market plays a critical job in giving clinical devices custom-made to address the one-of-a-kind neurological need of children, covering a scope of conditions from epilepsy to neurodevelopmental disorders.
There is a developing emphasis on early mediation in pediatric neurology, influencing market dynamics. Clinical devices designed for formative neurology, including checking systems for early signs of neurological disorders, are acquiring significance in further developing outcomes for children with neurological challenges.
The increasing frequency of pediatric neurological disorders is a critical driver in market dynamics. Conditions such as autism spectrum disorders, attention deficit hyperactivity disorder (ADHD), and epilepsy are adding to the developing interest for specialized neurology devices for children.
Wearable and compact devices are acquiring noticeable quality in pediatric neurology, affecting market dynamics. Innovations such as compact EEG monitors and walking checking systems give greater adaptability in observing neurological action, empowering continuous information assortment outside customary clinical settings.
The coming of precision medication and advancements in pediatric neurogenetics are shaping the market. Genetic testing and personalized treatment approaches based on a singular child's genetic profile add to focused on and successful interventions, impacting market dynamics in pediatric neurology.
Parental association in the selection of neurology devices for their children is affecting market dynamics. Device manufacturers consider the preferences, ease of use, and comfort levels for parents and caregivers, affecting the reception rates of pediatric neurology devices.
The market dynamics are advancing with the mix of telehealth and remote checking solutions in pediatric neurology. These technologies improve accessibility to neurological consideration, empowering remote consultations, observing, and follow-up, adding to more persistent driven and inclusive consideration models.
OrthoPediatrics announced early in January 2024 that it had acquired Boston Orthotics & Prosthetics at an undisclosed amount. In addition to the acquisition, OrthoPediatrics has signed a debt financing agreement with MidCap Financial and could raise up to $80 million of capital by combining a term loan with the revolving loan, replacing the previous unused $50 million line of credit.
Oxford Nanopore Technologies teamed up with American firm Fabric Genomics in October 2023 to create software capable of analyzing and reporting genomic information from neonatal and pediatric patients in ICUs.
Axoft launched its brain-machine interface (BMI) for the treatment of long-term neurological disorders with the FDA Breakthrough Device designation in October 2022. This minimally invasive device offers electrical stability to monitor brain signals and a high number of sensors per volume unit on it to optimize the amount of information that can be communicated between living brains and circuits.
Abbott got US Food and Drug Administration (FDA) approval for its new spinal cord stimulation device—a new modality called FlexBurst360™ therapy within the Proclaim™ Plus spinal cord stimulation (SCS) system—in August 2022. It provides pain coverage over as many as six sites on limbs while mimicking natural patterns observed inside human brain neurons.
Medtronic plc disclosed United States FDA clearance news in July 2021, where they performed their initial operations related to Deep Brain Stimulation (DBS) using the SenSight directional lead system. The SenSight was a one-of-a-kind DBS directional lead that combined directionality advantages with sensing capabilities, thus allowing physicians to achieve accurate patient-specific DBS therapy addressing certain movement disorders symptoms such as Parkinson’s disease, dystonia and essential tremor, and medically refractory epilepsy.
gammaCore Sapphire was approved by the US Food and Drug Administration (FDA) in February 2021 as an acute, preventive treatment for migraine in adolescents aged between twelve to seventeen years. It is a handheld, non-invasive device that applies a low-voltage electric signal resulting in an electrical field close to the vagus nerve thereby averting and relieving headaches without any need to undergo surgery.
The pediatric neurology devices market is segmented on the basis of type, service and treatment, neurological subspecialties, age group, and end user
By type, the pediatric neurology devices market is segmented into neurosurgery devices, neurostimulator, cerebrospinal fluid (CSF) management devices, and others.
On the basis of service and treatment, pediatric neurology devices market is segmented into electroencephalogram, intrathecal baclofen therapy, neurological evaluations, vagal nerve stimulation, and others.
On the basis of the neurological subspecialties, pediatric neurology devices market is segmented into neuro-oncology, neuromuscular, neonatal neurology, neuro-immunology, stroke, and others.
On the basis of the age group, pediatric neurology devices market is segmented into neonates, infants, children, and adolescents
On the basis of the end user, pediatric neurology devices market is segmented into hospitals, healthcare centers, neurological research centers, and others.
The Americas dominate the market owing to the rising prevalence of disease such as depression, epilepsy, and migraine, high healthcare spending, and increasing government support for research & development. According to a report published by the Centers for Disease Control and Prevention in 2017, more than 470,000 children below 17 years have epilepsy. Additionally, According to the Migraine Research Foundation, (2014), migraine was the 3rd most prevalent illness in the world. Nearly 1 in 4 U.S. households includes a migraine patient.
Europe holds the second position in the market owing to the government support for research & development and availability of funds for research. Moreover, people of this region have more healthcare awareness. This is expected to continue to drive the European market over the forecasted period.
Asia Pacific is considering the huge market for pediatric neurology devices market players owing to the presence of huge patient population in countries like India and china. Moreover, high health care expenditure, adding the fuel to this market. Additionally, countries from this region looking forward to adopt advanced technology and treatment from developed nations to improve the quality of life for their citizen.
Whereas the Middle East and Africa are considering the low market due to incapability of investment and poor healthcare infrastructure.
Intended Audience
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)